KRAS and non-small cell lung carcinoma: Despite a well-delineated genetic and functional profile, KRAS has long been deemed a challenging “undruggable target,” a notion that persisted until recent FDA approvals of drugs Sotorasib [7] and Adagrasib [8], which target the KRASG12C mutation in treating non-small cell lung cancer (NSCLC).